The alerting expression of microRNA-411 predicts clinical prognosis and regulates tumor progression of glioblastoma. Issue 1 (1st January 2021)

• Record Type: Journal Article
• Authors: Fan, Weihua; Yu, Xia; Li, Kunrong; Zhu, Mingtao
• Is Part Of: Bioengineered. Volume 12:Issue 1(2021)
• Page Start: 8650
• Page End: 8657
• Publication Date: 2021-01-01
• Subjects: miR-411 -- glioblastoma -- tumor progression -- prognosis; Biomedical engineering -- Periodicals; Biotechnology -- Periodicals; Microbiology -- Periodicals; 660.6
• DOI: 10.1080/21655979.2021.1988365
• Languages: English
• ISSNs: 2165-5987

Abstract

ABSTRACT: Glioblastoma is a malignant intracranial tumor with indispensable growth. Identification of biomarkers associated with the progression of tumors could benefit the clinical therapy of and improve patient's survival. miR-411 has been reported to play a role in other cancers, while its function in glioblastoma has been explored in the present study. The expression of miR-411 was evaluated in glioblastoma tissues (collected from 108 glioblastoma patients) and cells by polymerase chain reaction. The clinical significance of miR-411 was estimated with a series of statistical analyses. The biological function of miR-411 in the cellular processes of glioblastoma was assessed by cell counting kit 8 and Transwell assay. The expression of miR-411 was significantly reduced in glioblastoma, which was associated with the Karnofsky Performance Score (KPS) and Isocitrate dehydrogenase 1 (IDH1) status of patients. miR-411 was identified as an independent prognostic indicator that correlated with the poor prognosis of patients. miR-411 suppressed the growth, migration, and invasion of glioblastoma cells via modulating signal transducer and activator of transcription 3 (STAT3). miR-411 participated in the development of glioblastoma and function as a prognostic biomarker. miR-411 functions as a tumor suppressor, which provides a novel potential therapeutic target for glioblastoma.